

Clinical Phase 2 trial of DD01, a Novel Long-acting GLP-1/GCG dual agonist in patients with MASH

D&D Pharmatech Inc.



METABOLIC	Phase 2a
Product Type	Recombinant Protein
Indication	Metabolic-Associated Steatohepatitis (MASH) with Fibrosis (F2-F3)
Target	GLP-1 and Glucagon receptor (Dual agonist)
MoA(Mechanism of Action)	DD01 is a GLP-1/Glucagon receptor dual agonist with a GLP-1R biased ratio, reducing hepatic steatosis, improving fibrosis, and addressing metabolic comorbidities through enhanced energy expenditure and lipid metabolism
Competitiveness	<ul style="list-style-type: none"> • Rapid improvements in liver health • One-stop treatment addressing problems with liver, obesity, and poor glucose control • Well-tolerated, no need to titrate • First-line treatment opportunity for obese and diabetic with MASLD/MASH
Development Stage	Phase 2a
Route of Administration	Subcutaneous injection (weekly)

Any unauthorized distribution or reproduction of this material is strictly prohibited.